Phase 1 trial of a 13-valent pneumococcal conjugate vaccine in healthy adults (Q34650255)

3 August 2017

Phase 1 trial of a 13-valent pneumococcal conjugate vaccine in healthy adults (English)

1 reference

pneumococcal conjugate vaccine

3 August 2017

phase I clinical trial

0 references

vaccine

1 reference

based on heuristic

inferred from title

1 reference

7

William Gruber

1 reference

3 August 2017

Daniel A Scott

1

1 reference

3 August 2017

Steven F Komjathy

2

1 reference

3 August 2017

Branda T Hu

3

1 reference

3 August 2017

Sherryl Baker

4

1 reference

3 August 2017

Lois A Supan

5

1 reference

3 August 2017

Carol A Monahan

6

1 reference

3 August 2017

George R Siber

8

1 reference

3 August 2017

Stephen P Lockhart

9

1 reference

3 August 2017

language of work or name

English

0 references

publication date

26 June 2007

1 reference

3 August 2017

3

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

3 August 2017

25

1 reference

3 August 2017

33

1 reference

3 August 2017

6164-6166

1 reference

Decline in Invasive Pneumococcal Disease after the Introduction of Protein–Polysaccharide Conjugate Vaccine

3 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.004

The contribution of specific pneumococcal serogroups to different disease manifestations: implications for conjugate vaccine formulation and use, part II.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.004

Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.004

Postvaccine genetic structure of Streptococcus pneumoniae serotype 19A from children in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.004

Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.004

Approach to validating an opsonophagocytic assay for Streptococcus pneumoniae

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.004

Effect of human immunodeficiency virus type 1 infection on the antibody response to a glycoprotein conjugate pneumococcal vaccine: results from a randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.004

Tolerability and immunogenicity of an 11-valent pneumococcal conjugate vaccine in adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.004

Significant variation in serotype-specific immunogenicity of the seven-valent Streptococcus pneumoniae capsular polysaccharide-CRM197 conjugate vaccine occurs despite vigorous T cell help induced by the carrier protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.004

Pneumococcal conjugate vaccination in adults: circulating antibody secreting cell response and humoral antibody responses in saliva and in serum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.004

Antibody responses to polysaccharide and polysaccharide-conjugate vaccines after treatment of Hodgkin disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.004

IgG response to pneumococcal polysaccharide-protein conjugate appears similar to IgG response to polysaccharide in bone marrow transplant recipients and healthy adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.06.004

10.1016/J.VACCINE.2007.06.004

7 January 2021

Identifiers

DOI

1 reference

3 August 2017

1 reference